Pain News and Research

Latest Pain News and Research

InSite Vision to advance new development candidate ISV-303

InSite Vision Incorporated, a company developing ophthalmic products for unmet eye care needs, today announced plans to advance new development candidate ISV-303, a topical anti-inflammatory product intended to reduce the pain and swelling associated with ocular surgery.

16 Dec 2009

Spinal Restoration receives FDA SPA concurrence letter for its Phase 3 Biostat System study

Spinal Restoration, Inc. announced today it has received a Special Protocol Assessment concurrence letter from the U.S. Food and Drug Administration (FDA) for the design of its Phase 3 study of the Biostat System for the treatment of chronic discogenic low back pain.

15 Dec 2009

Jazz Pharmaceuticals announces submission of JZP-6 NDA for treatment of fibromyalgia

Jazz Pharmaceuticals, Inc. announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for JZP-6 (sodium oxybate oral solution) for the treatment of fibromyalgia.

15 Dec 2009

Antidepressant and anti-anxiety medications linked to increased risk of cardiovascular events and death

Women with suspected coronary artery disease (CAD) who report taking antidepressant and anti-anxiety medications have an increased risk of cardiovascular events, including heart attacks and strokes, and death compared to women not taking these medications, according to researchers at the Uniformed Services University of the Health Sciences (USU).

15 Dec 2009

Florida doctor performs new, effective treatment for sinusitis

Local physician William Laskowski, MD has become the first doctor in Florida to perform an effective new treatment for sinusitis called FinESS® Sinus Treatment in an office setting. FinESS® (Entellus Medical, Maple Grove, MN) is a balloon sinuplasty option that is less-invasive than traditional sinus surgery and breaks the cycle of chronic or recurrent sinusitis with immediate relief and lasting results.

15 Dec 2009

Study explores comorbidity of medical complaints and insomnia symptoms in school-aged children

A study in the Dec. 15 issue of the Journal of Clinical Sleep Medicine indicates that significant associations exist between parent-reported insomnia symptoms and medical complaints of gastrointestinal regurgitation and headaches in young school-aged children.

15 Dec 2009

ProChon Biotech announces expansion of BioCart Cartilage Regeneration System study

ProChon Biotech, Ltd., an innovator of tissue regenerative technologies that are being developed to relieve pain and restore the mobility and quality of life for sufferers of articular cartilage injuries, today announced a significant expansion of its clinical study of the BioCart™ Cartilage Regeneration System.

15 Dec 2009

Celebrex stops aspirin from doing its job effectively

Millions of Americans take Celebrex for arthritis or other pain. Many, if they are middle-aged or older, also take a low-dose aspirin tablet daily to reduce the risk of heart attack and stroke. Yet they may be getting little protection, because Celebrex keeps the aspirin from doing its job effectively, a new study suggests.

15 Dec 2009

UCB offers tips for managing rheumatoid arthritis during festive season

A third of women living with rheumatoid arthritis say their disease impacts their enjoyment of the festive season - Women living with rheumatoid arthritis find shopping for gifts, preparing holiday food, writing cards and wrapping presents most difficult to do - Nearly two thirds of women living with rheumatoid arthritis experience pain daily

14 Dec 2009

Cell-enriched breast reconstruction procedure improves breast deformity in lumpectomy patients

Interim results from a European clinical trial, RESTORE 2, demonstrate that cell-enriched breast reconstruction achieved a high rate of patient and physician satisfaction and improvements in overall breast deformity in lumpectomy patients.

14 Dec 2009

Genentech announces positive results from Phase II study of T-DM1

Genentech, Inc., a wholly owned member of the Roche Group, today announced positive results from a Phase II study of trastuzumab-DM1 (T-DM1). As assessed by independent review, T-DM1 shrank the tumors (also known as objective response) in 33 percent of women with advanced (metastatic) HER2-positive breast cancer that had worsened following previous treatment.

14 Dec 2009

ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of positive trastuzumab-DM1 (T-DM1) clinical data at the 32nd Annual San Antonio Breast Cancer Symposium (Abstract #710).

14 Dec 2009

Modified blood adult stem-cell transplant regimen reverses sickle cell disease

A modified blood adult stem-cell transplant regimen has effectively reversed sickle cell disease in 9 of 10 adults who had been severely affected by the disease, according to results of a National Institutes of Health study in the Dec. 10 issue of the New England Journal of Medicine.

13 Dec 2009

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Ambit Biosciences Corporation announced today the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid leukemia (AML).

11 Dec 2009

Proteins from catfish venom glands could accelerate wound healing in humans

Lest anyone have concerns about attacks of killer catfish, rest assured that, at least in North America, these finned fatales use their venom mainly to defend themselves against predatory fish, though they can inflict a painful sting that many fishermen have suffered. In other parts of the world, some catfish do have extremely toxic venoms that can be deadly to humans.

11 Dec 2009

University of Maryland School of Nursing to spearhead new Center for Pain Studies

The University of Maryland School of Nursing in Baltimore is "uniquely poised" to spearhead a new collaborative Center for Pain Studies funded by a $2.4 million, five-year federal grant, said Susan Dorsey, PhD, RN, director of the center.

11 Dec 2009

Oconomowoc Memorial Hospital performs partial knee resurfacing surgery using MAKOplasty technology

For the first time in Wisconsin, patients suffering from arthritis pain have access to a new procedure that uses the precision of robotics to perform partial knee resurfacing surgery. The technology, called MAKOplasty®, is a minimally invasive surgical option that results in shorter hospital stays and faster healing than traditional knee surgeries.

11 Dec 2009

FDA approves Lannett's Hydromorphone Hydrochloride Tablets

Lannett Company, Inc. today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Applications (ANDAs) for Hydromorphone Hydrochloride Tablets USP, 2 mg, 4 mg and 8 mg, the generic equivalent of Purdue Pharmaceuticals’ (formerly Abbott’s) Dilaudid® Tablets 2 mg, 4 mg and 8 mg.

11 Dec 2009

Drop in U.S. colorectal cancer deaths

The American Society for Gastrointestinal Endoscopy (ASGE) lauds the recent news of the decline in U.S. colorectal cancer death and incidence rates. The report, released this week, shows that from 1975 to 2000, incidence rates dropped 22 percent and death rates dropped 26 percent.

10 Dec 2009

Salix Pharmaceuticals discusses proposed rifaximin NDA with the FDA

Salix Pharmaceuticals, Ltd. today reported that the Company held a pre-NDA meeting on December 8, 2009 with the FDA to discuss the Company’s proposed new drug application (NDA) for rifaximin in the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS).

10 Dec 2009